Cardiome Pharma Corp. (CRME) Posts Q1 Loss of 20c/Share

Cardiome Pharma Corp. (NASDAQ: CRME) reported Q1 EPS of ($0.20), $0.09 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $7.6 million versus the consensus estimate of $8.08 million.

For earnings history and earnings-related data on Cardiome Pharma Corp. (CRME) click here.

You May Also Be Interested In

• L3Harris CEO steps down amid conduct review, shares drop
• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• The LGL Group (LGL) Misses Q2 EPS by 8c